Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations

  • R. Foley McMaster University, Juravinski Hospital and Cancer Centre
  • R. Kaedbey McGill University, Sir Mortimer B. Davis Jewish General Hospital
  • K. Song University of British Columbia, Vancouver General Hospital
  • C.P. Venner University of Alberta, Cross Cancer Institute
  • D. White Dalhousie University, Queen Elizabeth
  • S. Doucette IMPACT Medicom Inc.
  • A. Christofides IMPACT Medicom Inc
  • D.E. Reece University of Toronto, Princess Margaret Cancer Centre, University Health Network
Keywords: multiple myeloma; COVID-19; corona virus; coronavirus

Abstract

 

The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that patients with multiple myeloma are at increased risk of covid-19 infection and related complications, national bodies and experts around the globe have made recommendations for risk mitigation strategies for those vulnerable patients. Understandably, because of the novelty of the virus, many of the proposed risk mitigation strategies have thus far been reactionary and cannot be supported by strong evidence. In this editorial, we highlight some of the risk mitigation strategies implemented at our institutions across Canada during the first wave of covid-19, and we discuss the considerations that should be made when managing patients during the second wave and beyond.


Published
2020-10-20
How to Cite
Foley, R., Kaedbey , R., Song, K., Venner, C., White, D., Doucette, S., Christofides, A., & Reece, D. (2020). Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations. Current Oncology, 27(5). https://doi.org/10.3747/co.27.7149
Section
Short Communication